126 материалов по теме, собраны автоматически из проверенных источников
Bringing Innovation Closer to Home: Expanding Access to Immunotherapy Through Community Oncology ASCO Connection
2026 ACI: A Focus on Neoadjuvant Immunotherapy Oncodaily
Экспериментальная CAR-T терапия помогла ребёнку с раком печени Techinsider.ru
Иммунотерапия при онкологии: как врачи используют клетки пациентов для борьбы с раком Доктор Питер
Иммунотерапия при онкологии: как врачи используют клетки пациентов для борьбы с раком Доктор Питер
Immunõ 2026: Where Is Cancer Immunotherapy Heading Next? Oncodaily
Yorkshire Cancer Research COVID-19 Vaccination and Immunotherapy Funding Round 2026 oncodaily.com
Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown role for B cells, adaptive immune cells, in triggering and sustaining colitis as a side effect of immune checkpoint inhibitors, a widely used form of cancer immunotherapy.
Mayo Clinic researchers have identified a strategy that could help chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, overcome a major barrier to treating solid tumors: Cancer cells can change in ways that allow them to hide from immune cells designed to attack them.
Study Shows Reprogramming Thyroid Tumors May Improve CAR-T Cell Therapy | Newswise Newswise
One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute scientists reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells…
Cancer is the second-leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives innovations that revolutionize cancer care—innovations like immunotherapy. Immunotherapy fights cancer using the body's own immune…
CARE study reports complete regression of liver cancer in a child treated with novel immunotherapy Baylor College of Medicine Blog Network -
A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced RCC Oncology Central
Two patients receive the same immunotherapy for the same cancer. In one, the tumor retreats and stays gone for years. In the other, the treatment does nothing. Oncologists still have no reliable way to tell these patients apart before therapy begins. Why does immunotherapy succeed for some and fail for others?